Pre-made Dapirolizumab benchmark antibody ( Fab, anti-CD40LG therapeutic antibody, Anti-IGM/IMD3/TRAP/gp39/CD154/CD40L/HIGM1/T-BAM/TNFSF5/hCD40L Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-132
Awaiting product image

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-132 Category Tag

For more than 100mg, click here for inquiry. >>

inquire

Product Details

Pre-Made Dapirolizumab biosimilar, Fab, Anti-CD40LG Antibody: Anti-IGM/IMD3/TRAP/gp39/CD154/CD40L/HIGM1/T-BAM/TNFSF5/hCD40L therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Dapirolizumab biosimilar, Fab, Anti-CD40LG Antibody: Anti-IGM/IMD3/TRAP/gp39/CD154/CD40L/HIGM1/T-BAM/TNFSF5/hCD40L therapeutic antibody
INN Name

Dapirolizumab
Target

CD40LG
Format

Fab
Derivation

NA
Species Reactivity

Human
CH1 Isotype

IgG1
VD LC

Kappa
Highest_Clin_Trial (Jan '20)

Phase-III
Est. Status

Active
100% SI Structure

None
99% SI Structure

None
95-98% SI Structure

None
Year Proposed

2013
Year Recommended

2014
Companies

Biogen,Biogen Idec,UCB
Conditions Approved

NA
Conditions Active

Systemic lupus erythematosus,Multiple sclerosis
Conditions Discontinued

Amyotrophic lateral sclerosis,Rheumatoid Arthritis
Development Tech

NA
Previous Name

NA
Gm Offical Target Name

CD40LG
Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide